Quintrio
Home

Stock overview

Stevanato Group S.p.A.

STVN

Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.

Last trade $15.64
Day change +$0.11 (+0.71%)
Day range $15.27 – $16.01
Volume 406,250
Market cap $4.24B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for STVN.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for STVN.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates

Stevanato Group (STVN) reported Q3 2026 earnings of $0.18 per share, beating consensus estimates of $0.17, with revenues of $375.28 million exceeding expectations by 3.14%. However, the stock has underperformed the S&P 500 by 12.1% year-to-date. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Meanwhile, peer company 4D Molecular Therapeutics is expected to report a quarterly loss of $1.04 per share.

Zacks Investment Research

United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?

United Therapeutics shares surged 12.5% following a Delaware court ruling that Liquidia's Yutrepia infringes on UTHR's patent for inhaled treprostinil, potentially restricting competition for UTHR's Tyvaso products. However, the stock faces headwinds as consensus EPS estimates were revised 1.4% lower over the past 30 days, and the company is expected to report declining earnings and flat revenue growth.

Zacks Investment Research

electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?

electroCore (ECOR) shares surged 6.9% to $11.38 following raised 2026 revenue-growth outlook of over 30% and improved operating performance. Q2 revenues increased 28% YoY to $9.5 million with narrowed adjusted EBITDA losses. However, the stock carries a Zacks Rank #3 (Hold) as earnings estimate revisions have remained flat over the past 30 days.

GlobeNewswire Inc.

Pharmaceutical Glass Packaging Market Forecast: Growth from USD 5.32 Billion in 2025 to USD 12.39 Billion by 2035

The global pharmaceutical glass packaging market is projected to grow from USD 5.32 billion in 2025 to USD 12.39 billion by 2035, with a CAGR of 8.82%. Growth is driven by rising demand for injectables, biologics, and GLP-1 therapies, alongside stringent EU regulatory requirements for sustainability and anti-counterfeiting measures. Europe, particularly Germany, is expected to be a major growth contributor.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jun 11, 2026€0.054Jul 29, 2026recurring
Jun 5, 2025€0.054Jul 17, 2025recurring
Jun 4, 2024€0.053Jul 15, 2024recurring
Jun 7, 2023€0.054Jul 17, 2023recurring
Jun 13, 2022€0.051Jul 13, 2022recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.